Table 1.
n | |
---|---|
Total number of assessable patients | 23 |
Age at study entry, years | 63.2±11.3 |
HER2/neu positive (%) | 12 |
ER positive (%) | 100 |
PR positive (%) | 100 |
Grading (%) | |
2 | 56.6 |
3 | 43.4 |
Sites of metastases at study entry (%) | |
Visceral | 13.1 |
Bone | 86.9 |
CTC+ | 100 |
Integrin β4+ CTCs+/total | 61 |
HER2/neu: Human epidermal growth factor receptor 2, ER: Estrogen receptor, CTCs: Circulating tumor cells, PR: Progesterone receptor